NASDAQ:CNTX Context Therapeutics (CNTX) Stock Price, News & Analysis $1.82 +0.03 (+1.68%) (As of 07/5/2024 ET) Add Compare Share Share Today's Range$1.73▼$1.8350-Day Range$1.33▼$2.1952-Week Range$0.77▼$2.24Volume51,385 shsAverage Volume540,041 shsMarket Capitalization$136.50 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Context Therapeutics alerts: Email Address Context Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside229.7% Upside$6.00 Price TargetShort InterestHealthy1.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.36) to ($0.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.06 out of 5 starsMedical Sector518th out of 879 stocksPharmaceutical Preparations Industry243rd out of 418 stocks 3.5 Analyst's Opinion Consensus RatingContext Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageContext Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Context Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.71% of the float of Context Therapeutics has been sold short.Short Interest Ratio / Days to CoverContext Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Context Therapeutics has recently decreased by 15.15%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldContext Therapeutics does not currently pay a dividend.Dividend GrowthContext Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CNTX. Previous Next 0.6 News and Social Media Coverage Search Interest8 people have searched for CNTX on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Context Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.30% of the stock of Context Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 14.03% of the stock of Context Therapeutics is held by institutions.Read more about Context Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Context Therapeutics are expected to grow in the coming year, from ($0.36) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Context Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Context Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioContext Therapeutics has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Context Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. About Context Therapeutics Stock (NASDAQ:CNTX)Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Read More CNTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CNTX Stock News HeadlinesMay 22, 2024 | investorplace.comThe 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit GainsMay 16, 2024 | msn.comPiper Sandler Initiates Coverage of Context Therapeutics (CNTX) with Overweight RecommendationJuly 6, 2024 | Paradigm Press (Ad)Biden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.May 16, 2024 | markets.businessinsider.comOptimistic Outlook for Context Therapeutics’ CTIM-76 Based on Targeting Efficacy and Market PotentialMay 11, 2024 | msn.comContext Therapeutics Posts Strong Q1 Financials, Advances Key Cancer Drug TrialsMay 9, 2024 | investorplace.comCNTX Stock Earnings: Context Therapeutics Beats EPS for Q1 2024May 8, 2024 | globenewswire.comContext Therapeutics Reports First Quarter 2024 Operating and Financial ResultsMay 3, 2024 | msn.comContext Therapeutics Raises $100 Million in Private Placement to Propel Clinical TrialsJuly 6, 2024 | Paradigm Press (Ad)Biden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.May 3, 2024 | msn.comContext Therapeutics Secures $100 Million in Private Placement to Fuel Clinical TrialsMay 2, 2024 | msn.comWall Street Set to Open Higher Thursday After Fed Holds Rate Steady, Jobless Claims Lower Than ExpectedMay 2, 2024 | finance.yahoo.comContext Therapeutics Announces $100 Million Private PlacementMay 2, 2024 | globenewswire.comContext Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76April 3, 2024 | msn.comContext Therapeutics Takes Bold Step with IND Submission for Groundbreaking Cancer TherapyApril 2, 2024 | cnn.comContext Therapeutics, Inc.April 1, 2024 | markets.businessinsider.comContext Therapeutics Submits IND For CTIM-76April 1, 2024 | globenewswire.comContext Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive CancersMarch 22, 2024 | markets.businessinsider.comBuy Rating Justified by Advances in T Cell Engagers and Context Therapeutics’ Strategic Drug PositioningSee More Headlines Receive CNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/06/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CNTX CUSIPN/A CIK1842952 Webwww.contexttherapeutics.com Phone267-225-7416FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$10.00 Low Stock Price Target$4.50 Potential Upside/Downside+229.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-136.03% Return on Assets-109.54% Debt Debt-to-Equity RatioN/A Current Ratio4.23 Quick Ratio4.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.74 per share Price / Book2.46Miscellaneous Outstanding Shares75,000,000Free Float65,773,000Market Cap$136.50 million OptionableNot Optionable Beta2.30 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Martin A. Lehr (Age 40)Co-Founder, President, CEO & Director Comp: $674.08kMs. Jennifer Minai-Azary (Age 46)CFO & Treasurer Comp: $504.14kMr. Alex C. Levit Esq. (Age 45)Chief Legal Officer & Corporate Secretary Comp: $483.83kMr. Christopher Beck M.B.A.Senior Vice President of OperationsKey CompetitorsMetacrineNASDAQ:MTCRUnicycive TherapeuticsNASDAQ:UNCYCatalyst BiosciencesNASDAQ:CBIOPharming GroupNASDAQ:PHARSilence TherapeuticsNASDAQ:SLNView All CompetitorsInstitutional OwnershipOpaleye Management Inc.Bought 133,357 shares on 5/29/2024Ownership: 1.478%View All Institutional Transactions CNTX Stock Analysis - Frequently Asked Questions How have CNTX shares performed this year? Context Therapeutics' stock was trading at $1.13 on January 1st, 2024. Since then, CNTX shares have increased by 61.1% and is now trading at $1.82. View the best growth stocks for 2024 here. How were Context Therapeutics' earnings last quarter? Context Therapeutics Inc. (NASDAQ:CNTX) issued its earnings results on Wednesday, May, 8th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.15. When did Context Therapeutics IPO? Context Therapeutics (CNTX) raised $25 million in an initial public offering (IPO) on Wednesday, October 20th 2021. The company issued 5,000,000 shares at $5.00 per share. How do I buy shares of Context Therapeutics? Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CNTX) was last updated on 7/6/2024 by MarketBeat.com Staff From Our Partners50-year Wall Street Legend Issues July Stock WarningJuly is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredBill Gates is all about this tiny $2 stockWhat does Bill Gates know about this tiny company that we don’t? From the outside, it looks like a worthles...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
